Candel’s promising Ph2 data in pancreatic cancer; Microbiome biotech raises £27M

Plus, news about Man­i­fold and Phe­nomix:

Can­del Ther­a­peu­tics’ vi­ral im­munother­a­py im­press­es in pan­cre­at­ic can­cer: In a small Phase 2 tri­al for pa­tients with bor­der­line re­sectable pan­cre­at­ic can­cer, those who re­ceived Can­del’s ex­per­i­men­tal ther­a­py had 28.8 months of es­ti­mat­ed over­all sur­vival time com­pared to the 12.5 months in those who re­ceived stan­dard chemo. Four of sev­en pa­tients who re­ceived CAN-2409 were still alive at the March 29 da­ta cut-off, with two pa­tients sur­viv­ing more than four years from en­roll­ment. On­ly one out of six pa­tients who re­ceived chemother­a­py was still alive. Can­del’s stock $CADL rose near­ly 40% on Thurs­day morn­ing. — Lei Lei Wu

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.